---
title: "Key facts: Novo Nordisk launches GLP-1 pill; faces generics competition; partners with Hims"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278188900.md"
description: "Novo Nordisk has launched the first GLP-1 pill for obesity, enhancing its position in the oral weight-loss drug market. However, it may face competition from generics of its GLP-1 drugs, Ozempic and Wegovy, which could be produced at significantly lower costs. Additionally, Novo Nordisk has settled its legal dispute with Hims & Hers Health and is set to partner with them to sell its weight-loss drugs on their platform, with an announcement forthcoming."
datetime: "2026-03-07T02:03:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278188900.md)
  - [en](https://longbridge.com/en/news/278188900.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278188900.md)
---

# Key facts: Novo Nordisk launches GLP-1 pill; faces generics competition; partners with Hims

-   Novo Nordisk has released the first GLP-1 pill for obesity, strengthening its role in the growing oral weight-loss drug market as competitors develop similar treatments.1
-   Novo Nordisk may face competition for its GLP-1 drugs, Ozempic and Wegovy, as generics of semaglutide could be produced for under $3 monthly, impacting costs significantly.2
-   Novo Nordisk has resolved its legal dispute with Hims & Hers Health, forming a partnership to sell its weight-loss drugs on Hims' platform, with an announcement expected soon.3

### Related Stocks

- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [HIMY.US](https://longbridge.com/en/quote/HIMY.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [08:31 ETFirst Program Designed Specifically For Women On GLP-1 In Perimenopause Targets Muscle Loss And Metabolism After 40](https://longbridge.com/en/news/282544747.md)
- [Why Is Hims & Hers Stock Soaring After FDA's Announcment?](https://longbridge.com/en/news/282988297.md)
- [Key facts: Novo Nordisk India rivals; 7.8k job cuts; less lean mass loss](https://longbridge.com/en/news/283077841.md)
- [Novo Nordisk (0QIU) Receives a Hold from Jefferies](https://longbridge.com/en/news/282799060.md)
- [Hims & Hers' Shift to Branded Obesity Drugs Pressures Stock — Will the Bet Pay Off?](https://longbridge.com/en/news/282190695.md)